"EverZom Secures €10 Million Funding Round for Innovative Exosome-Based Therapies"

"McDermott Will & Schulte advised EverZom on a €10 million funding round aimed at developing innovative exosome-based therapies for inflammatory and regenerative diseases. The funding, supported by various investors including Capital Grand Est and Sorbonne Venture, will help EverZom enter clinical phase by 2026 with its first therapeutic candidate for treating Crohn's perianal fistula, affecting thousands globally. The McDermott team included Emmanuelle Trombe, Lucie Martin, Oriana Castelli, and Alice Villagrasa."

McDermott Will & Schulte advised EverZom in its €10 million funding round aimed at developing innovative exosome-based therapies for the treatment of inflammatory and regenerative diseases. The fundraising round saw participation from several investors, including Capital Grand Est, EIC Fund, Sorbonne Venture, Aloe Private Equity, Paris Business Angels, and Capital Cell. The funds raised will enable EverZom to enter clinical phase by 2026 with its first therapeutic candidate developed for the treatment of Crohn's perianal fistula, a condition affecting thousands of patients worldwide. The McDermott team involved in this transaction included Emmanuelle Trombe (Partner), Lucie Martin (Counsel), and associates Oriana Castelli and Alice Villagrasa, all specializing in Life Sciences.

"EverZom Secures €10 Million Funding Round for Innovative Exosome-Based Therapies"

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads